RCS - Tern PLC - Talking Medicines record revenue bookings in Q1 24

TernAnnouncement

09/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240409:nRSI7579Ja&default-theme=true

RNS Number : 7579J  Tern PLC  09 April 2024

REACH - non-regulatory announcement

 

9 April 2024

 

Tern Plc

 

("Tern" or the "Company")

 

Talking Medicines reports record revenue bookings and strategic partnerships
in Q1 2024

 

Tern Plc (AIM:TERN), the investment company specialising in supporting high
growth, early-stage, disruptive Internet of Things ("IoT") technology
businesses, is pleased to note that Talking Medicines Limited ("Talking
Medicines"), a company in which Tern currently holds 23.8% of the equity, has
announced an update on its Q1 2024 performance, extracts of which are set out
below.

 

Extracts from the Talking Medicines announcement:

 

"Talking Medicines, a pioneering leader in healthcare intelligence leveraging
advanced data science and artificial intelligence, is pleased to announce a
strong start to 2024, marked by record revenue bookings and significant
advancements in its innovative platform, Talking Medicines Drug-GPT.

 

In the first quarter of 2024, Talking Medicines achieved significant success
with its Talking Medicines Drug-GPT platform, which aims to revolutionise
access to intelligence on pharmaceutical medicine brands and disease areas.
 This innovative technology has garnered substantial interest from leading
global healthcare advertising agencies, who recognise its potential to
transform strategies for pharmaceutical clients.

 

Among Talking Medicines' clients are some of the world's most prominent
healthcare advertising agency networks, reaffirming the platform's efficacy in
providing key insights derived from aggregated patient and healthcare
professional conversations.  By tapping into previously unseen data, Talking
Medicines empowers its clients to drive better strategies and make informed
decisions in relation to the pharmaceutical landscape.

 

Furthermore, Talking Medicines has forged strategic partnerships with both
open and closed data communities, solidifying its commitment to expanding
access to crucial insights.  Notable among these partnerships is the
collaboration with data aggregator Socialgist, which enables Talking Medicines
to tap into millions of public conversational sites, enriching the Talking
Medicines Drug-GPT platform with a wealth of diverse data sources.

 

Speaking on these achievements, Jo Halliday CEO expressed excitement about the
company's trajectory and the transformative impact of Talking Medicines
Drug-GPT on the healthcare industry: "We are thrilled by the broad response to
Talking Medicines Drug-GPT and our strategic partnerships. This success
underscores our dedication to empowering healthcare stakeholders with
actionable insights derived from advanced data science and artificial
intelligence."

 

Looking ahead, Talking Medicines remains committed to driving innovation and
fostering collaborations that enhance healthcare decision-making through
intelligence globally."

 

About Talking Medicines

 

Talking Medicines is a leading provider of healthcare intelligence, leveraging
advanced data science and artificial intelligence to transform pharmaceutical
brand strategies. The company's innovative platform, Talking Medicines
Drug-GPT, revolutionises access to intelligence on pharmaceutical medicine
brands and disease areas, empowering healthcare stakeholders with actionable
insights derived from aggregated patient and healthcare professional
conversations. For more information, visit: www.talkingmedicines.com
(http://www.talkingmedicines.com)

 

Enquiries

 

 Tern Plc                                                       via IFC Advisory

 Ian Richie

 Chairman

 Allenby Capital Limited                                        Tel: 0203 328 5656

 (Nominated Adviser and Broker)

 Alex Brearley / Dan Dearden-Williams (Corporate Finance)

 Kelly Gardiner / Guy McDougall (Sales and Corporate Broking)

 IFC Advisory                                                   Tel: 0203 934 6630

 (Financial PR and IR)

 Tim Metcalfe

 Graham Herring

 Florence Chandler

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPURUCUPCGRR